NVTH Course Venous Thrombosis – 30 March-1 April 2015
Golden Tulip Hotel Westduin–Koudekerke, Zeeland
Monday March 30
12.00 – 13.00
Registration and lunch
13.00 – 13.05
Introduction
Jeroen Eikenboom
13.05 – 13.30
Introduction in coagulation and thrombosis
Jeroen Eikenboom
13.30 – 14.15
Mechanisms of natural anticoagulants
Tilman Hackeng
14.15 – 15.00
Mechanisms of therapeutic anticoagulants
Michiel Coppens
15.00 – 15.30
Coffee break
15.30 – 16.10
Acquired risk factors for venous thrombosis
Astrid van Hylckama Vlieg
16.10 – 16.50
Genetic risk factors for venous thrombosis
ElisabettaCastoldi
16.50 – 17.30
Cancer and venous thrombosis
Henri Versteeg
17.30 – 19.30
Dinner
19.30 – 21.00
Masterclass
PhD students discuss own research
NVTH Course Venous Thrombosis – 30 March-1 April 2015
Golden Tulip Hotel Westduin–Koudekerke, Zeeland
Tuesday March 31
08.30 – 09.30
Diagnosis of venous thromboembolism
Menno Huisman
09.30 – 10.30
Prevention and treatment of venous thromboembolism
Frank Leebeek
10.30 – 11.00
Coffee break
11.00 – 12.00
Mouse models in venous thrombosis research
Bart van Vlijmen
12.00 – 13.00
Fibrinolysis
Shirley Uitte de Willige
13.00 – 14.00
Lunch
14.00 – 15.00
Post-thrombotic syndrome
Arina ten Cate
15.00 – 16.00
Chronic thromboembolic pulmonary hypertension
(CTEPH)
Erik Klok
16.00 – 17.00
Women’s issues in venous thrombosis
Saskia Middeldorp
17.00 -
Cooking workshop and dinner
NVTH Course Venous Thrombosis – 30 March-1 April 2015
Golden Tulip Hotel Westduin–Koudekerke, Zeeland
Wednesday April 1
08.30 – 09.30
Preparation debate
Papers
1. Meyer G et al., Fibrinolysis for patients with intermediaterisk pulmonary embolism. N Engl J Med 2014;370:1402-1411
2. van Es N et al., Direct oral anticoagulants compared with
vitamin K antagonists for acute venous thromboembolism:
evidence from phase 3 trials. Blood 2014;124:1968-1975
09.30 – 10.30
Debate
1. Intermediate risk pulmonary embolism should be
treated with fibrinolysis: Yes / No
Moderator Frank Leebeek
2. Direct oral anticoagulants should become the drugs of
first choice for the treatment of acute venous
thromboembolism even in absence of antidotes: Yes / No
Moderator Pieter Willem Kamphuisen
10.30 – 11.00
Coffee break
11.00 –11.30
Verbindende sessie met de Vereniging
Hematologische Laboratoria (VHL)
Laboratory measurement of direct oral anticoagulants
An Stroobant
11.30 –12.00
Quality control of new assays for direct oral
anticoagulants
Piet Meijer
12.00 – 13.00
Lunch